THE NAME
What is being offered?
If the word peptide makes an offer sound precise, unpack the word first.
Thymosin alpha-1 is a peptide: a small string of the parts used to make proteins.
It was first found in a chest gland called the thymus. That gland helps the body's defence network, known as the immune system, develop.
The lab-made version is called thymalfasin.
Researchers study its effects on immune cells. How it acts in people is still not fully settled.
An effect on immune cells does not, by itself, prove a health benefit.
US STATUS
Does an offer mean it is allowed?
If a website calls the medicine compounded, ask which ingredients the pharmacy may use to make it.
A compounded medicine is one a pharmacy or doctor prepares from ingredients.
At the September 2026 check, compounded drugs had no FDA approval. FDA does not assess their quality, whether they work, or their safety before sale.
The rules below concern which ingredients a pharmacy may use, rather than laboratory tests of a batch of medicine.
| What the rules require | What was found |
|---|---|
| Published rules for what the ingredient must be and how pure it must be | None applies to this ingredient, as of September 2026. |
| A place in an approved US drug | None, as of September 2026. |
| A place on the permitted ingredient list | As of September 2026, this ingredient is not listed. |
As of September 2026, thymosin alpha-1 does not qualify as an ingredient that an ordinary pharmacy may use to make medicine.
At the September 2026 check, FDA listed the request to allow this ingredient as taken back by the groups that made it.
As of September 2026, pharmacies gained no permission to make medicine from thymosin alpha-1 when that request was taken back.
What about approval abroad?
As of September 2026, Italy allows thymalfasin (Zadaxin) to be used with the flu vaccine for people whose body's defences are weak.
That permission in Italy does not allow sales in the US, under the rules checked in September 2026.
EVIDENCE
What can the studies actually tell you?
If an offer refers to research, ask which study and which health problem. A study can be real while the claim goes too far.
The FDA's 2024 review covered 12 proposed uses. It found that the studies were too weak to show that the medicine helped for any of those uses.
The studies have not shown that it helps for those uses. That does not mean it could never help.
A close look at the TESTS trial
The TESTS trial was published in 2025.
It studied adults in hospital with sepsis, a life-threatening reaction to an infection.
After 28 days, 23.4% of the drug group had died, compared with 24.1% of the dummy-shot group.
A dummy shot looks like treatment but contains no active medicine.
The trial found no clear reduction in deaths with the drug.
The maker, SciClone Pharmaceuticals, supported TESTS; some authors reported grants or fees from it.
This hospital study does not show a health benefit for a healthy adult.
Bring the claim back to your own reason for seeking care: what benefit is being proposed, and what evidence supports that use?
THE CARE PROCESS
What does getting care involve?
To choose between an online visit and a visit in person, first name the health problem you need help with.
Telehealth means a care visit by video, phone, or messages. An in-person clinic offers a visit in a room.
The telehealth rules checked in September 2026 require a licence or other permission covering the state the patient is in during the visit.
Find out who would assess you: get the full name of that doctor, nurse, or other licensed health professional. Ask which state board gives them permission to provide care.
A state medical board's public records let you check a doctor's licence and any action against them for breaking its rules.
A doctor's care quality cannot be judged from a record that lists no public action against them.
The medical board directory in the source cards below leads to the state's own records.
| When | What to bring or ask |
|---|---|
| Before the visit | Write down symptoms, current medicines, allergies, and what brought you to this topic. |
| During the review | What else could explain the problem? Which care choices have better evidence? |
| If a product is proposed | What exactly is it? Which pharmacy would make and send it? What supports its use here? |
| Before the visit ends | Who answers later questions? When is the plan reviewed? If the plan fails to help, what comes next? |
If you need a test or a physical exam, you may need to be seen in person. Medical board guidance says the doctor should either set up your needed tests or refer you to a person who can do so.
State licensing boards set up the Federation of State Medical Boards. In May 2026, the group said choosing a treatment from a website's list is not enough for a prescription. The doctor should assess your health first.
The group also says patients should be able to ask questions after the visit. These are the group's recommendations for good care. They do not set the law for every state. Each state sets its own rules.
A visit can lead to another care option, more assessment, or no prescription.
EFFECTS AND UNKNOWNS
What needs a closer care review?
If a page describes the substance as natural, the word still leaves the product and its effects to be checked.
FDA's 2024 review found that the problems reported most often were a sore, red, or irritated spot where the shot was given.
In those studies, the medicine was made to drug quality standards and given under a doctor's supervision. Those results do not tell us whether an unapproved product is safe.
As of September 2026, FDA says there is too little information to judge the safety of pharmacy-made thymosin alpha-1.
For shots, FDA is concerned that the body's defences may react against the peptide. It is also concerned about unwanted substances and how hard it is to confirm exactly what the ingredient contains.
Small peptide chains can stick together in clumps. The body may treat those clumps as something to fight, setting off its defences.
For thymosin alpha-1, no US information sheet reviewed by FDA covered who must avoid it or its effects in pregnancy, as of September 2026.
Tell the doctor about pregnancy, breastfeeding, allergies, any transplant, and any health problem affecting your body's defences. Include medicines that change or weaken those defences. If you are unsure, bring a full list of your health problems and medicines and ask the doctor to check it.
Ask what is known about the risks for someone with your health problems. Ask what symptoms would mean you need urgent help and who to call.
Offers to set aside
FDA lists a pharmacy offering prescription medicine without a prescription among its warning signs, in guidance checked in September 2026.
It also flags no state licence and no licensed pharmacist available for questions.
Ask for the pharmacy's name, then check it in your state board's licence records. The FDA pharmacy link below takes you to those records.
FDA says a pharmacy missing from that state lookup is one to avoid.
A licence alone does not show that the pharmacy is following the rules for making and supplying this medicine.
Ask which rule allows it to be made, what checks confirm its quality, and how it is stored and sent to you.
Do not use a bottle labelled 'for research use only' as your medicine. In letters checked in September 2026, FDA told sellers that a research label did not excuse selling unapproved medicines for people to use.
COST AND COVERAGE
What would the whole care offer cost?
If a page gives a monthly total, ask what it pays for and what happens after the first bill.
At the September 2026 check, there was no approved US product, so no US maker's list price for thymosin alpha-1 existed.
For a service under consideration, request a written total. Keep the price question beside the product and evidence questions.
| Part of the offer | Question to ask |
|---|---|
| Assessment | Is the first visit charged separately? If the visit ends without a prescription, what would you pay? |
| Medicine | Is it included in the displayed total or billed later? |
| Tests | Which tests are needed? Who bills for them? |
| Ongoing care | Are later reviews included, and what does a further visit cost? |
| Renewal | When does a starting price change? What repeats, and how can the arrangement end? |
| Insurance | Does the plan pay for any part? What exact service and product names does it need to check? |
Compare the same parts across offers. A low medicine figure and an all-in care total answer different questions.
For coverage, take the exact service and product names to the plan and ask for its answer in writing.
CLAIMS TO CHECK
What does a reassuring claim leave out?
If a badge, code, or short claim seems to settle the question, read the part it cannot answer.
Does a drug product number prove FDA approval?Read the check
FDA's drug list identifies a product with a number: its National Drug Code (NDC). As of September 2026, having that code does not mean FDA approval.
The thymosin alpha-1 products on FDA's drug list in September 2026 were powders for making medicine, rather than finished medicines.
Ask the provider to show you FDA's written approval for the exact finished medicine, with its name and maker. A product number or a place on the drug list is not that approval.
Does taking back a request let a pharmacy use the ingredient?Read the check
No. As of September 2026, withdrawing the request had given pharmacies no permission to use thymosin alpha-1 as an ingredient. FDA still lists safety concerns about the body's reaction to the shot, unwanted substances, and confirming what the ingredient contains.
Ask which rule allows the pharmacy to make the medicine being offered.
Does a hospital study show it helps healthy people?Read the check
The TESTS study involved adults with sepsis in hospital. Its results do not establish a benefit for healthy people.
Ask for evidence that matches the reason for seeking care, rather than a study of a different problem.
SOURCE CARDS
Records behind the guide, and places to check
Use the medical board and pharmacy lookups for the names in a care offer. Use the research and FDA records to inspect the claim.
- FDA review of thymosin alpha-1
Evidence, reported effects, and the ingredient concerns.
- FDA record of withdrawn ingredient requests
The request that was taken back and FDA's safety concerns. FDA marks this page as current on April 22, 2026.
- FDA ingredient rules for ordinary pharmacies
Rules about which ingredients a pharmacy may use.
- FDA explanation of compounding
What making medicine from ingredients means and what FDA approval covers.
- TESTS study in BMJ
The hospital trial shown in the chart and its funding disclosure.
- Italian medicines agency record
The national authorisation record for thymalfasin (Zadaxin).
- European medicines agency summary
Context for the narrow Italian use.
- Find a state medical board
Follow the directory to the state's own doctor licence records.
- Check a pharmacy with the state board
FDA links to the state licence searches.
- Medical board guidance on prescribing
A health review before a prescription, rather than just picking a treatment from a website's list, and questions after the visit.
- Medical board guidance on remote care
Licences, the care standard, and arranging tests or in-person review.
- FDA signs to look for in an online pharmacy
Prescription, licence, and pharmacist checks.